700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)Yoshinobu Miyatsu |
||
Biologics Development And Production Department, The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), 1314-1 Kyokushikawabe, Kikuchi, Kumamoto 869-1298 Japan |
||
Publications | ||
Immunotherapy is the only curative approach to treat allergy, but carries the risk of anaphylaxis. C8/119S is a mutant of Der f 2, which is one of the causative allergens of perennial allergic diseases, and has been selected to decrease the risk of anaphylaxis in immunotherapy. In this study, the physical properties of C8/119S were determined, and ... Read More» Satoshi Koyanagi*, Toshio Murakami, Kazuyuki Nakashima, Toshihiro Maeda, Yoshinobu Miyatsu, Keishin Sugawara and Hiroshi Mizokami Research Article: J Allergy Ther 2010, 1:105 |
||
|